---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016645"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:04:48.134819+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a

## Summary
- Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.
- Cash $654.6M; funding through 2025; year-end 2022 cash guided at $575-600M.
- XmAb564 Phase 1a: single-dose well-tolerated; 117-fold peak CD25 bright Treg expansion; Phase 1b in atopic dermatitis/psoriasis started.
- Vudalimab Phase 2 in mCRPC; plamotamab Phase 2 enrolling; data at SITC and ASH.
- Vir royalty $17.8M in Q3; Zenas raised $118M, plans Phase 3 for obexelimab.

## SEC filing metadata
- accession: 0001558370-22-016645
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/0001558370-22-016645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/xncr-20221107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016645
- JSON: https://secwatch.observer/filing/0001558370-22-016645.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016645.txt

## Key facts
- Earnings Releases
  Xencor Inc reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Xencor, Inc. announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/0001558370-22-016645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.